Search

Your search keyword '"Sigurdardottir, Margret"' showing total 146 results

Search Constraints

Start Over You searched for: Author "Sigurdardottir, Margret" Remove constraint Author: "Sigurdardottir, Margret"
146 results on '"Sigurdardottir, Margret"'

Search Results

2. Social Tie Formation of COVID-19 Students: Evidence from a Two-Cohort Longitudinal Study

3. Student Evaluation of Teaching: Gender Bias in a Country at the Forefront of Gender Equality

4. Monoclonal gammopathy of undetermined significance with multiple paraproteins: A population‐based screening study.

5. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study

7. Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study

9. Association Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance: An Analysis From a Population-Based Screening Study.

10. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance: A Cohort Study Nested in a Clinical Trial.

11. Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do

12. Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study

13. Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study

14. Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study

18. Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial. First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

19. Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

20. Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) Study

21. Monitoring of Circulating Tumor Plasma Cells in Patients with Precursor Conditions of Multiple Myeloma: Data from the Prospective Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

22. Estimating Selection Bias in Previous Monoclonal Gammopathy of Undetermined Significance Research - the Importance of Screening: Results from the Population-Based Screening Study Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM)

23. Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM)

25. Revised Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study

26. Monoclonal Gammopathy of Undetermined Significance and the Risk of Thrombotic Events: Results from Istopmm, a Population-Based Screening Study in Iceland

27. Sars-Cov-2 Infection Does Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study

28. Predicting an Underlying Clonal Plasma Cell Population in Light-Chain Monoclonal Gammopathy of Undetermined Significance Using Free Light-Chain Ratio

29. Risk Factors of Smoldering Multiple Myeloma: Results from the Screened Istopmm Study

30. The Early Benefits and Psychological Effects of Screening for Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study

31. SOCIAL TIE FORMATION OF COVID-19 STUDENTS: EVIDENCE FROM A TWO-COHORT LONGITUDINAL STUDY.

34. Signaling Similarity in the Icelandic Labour Market: How Can Immigrants Reduce Statistical Discrimination?

35. Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort

36. Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

37. Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study

38. Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

39. Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study

40. Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort

45. Hybrid Mismatch Arrangements Within EU: Under what Conditions could Single Taxation Be Secured?

50. Linkage of Osteoporosis to Chromosome 20p12 and Association to BMP2

Catalog

Books, media, physical & digital resources